Navigation Links
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
Date:1/15/2014

chemoradiation. The overall survival and locoregional control results were favorable in comparison to historical controls of chemoradiation without bevacizumab and warrant further study in a phase III trial.

"Parenthetically, when we were designing this trial, one thing we discussed at length was whether to include a maintenance phase of bevacizumab after chemoradiation. Because of perceived issues with patient compliance at the time, we decided not to add to the overall duration of treatment by adding maintenance Bevacizumab. Based on the recent results of GOG 240 which showed an overall survival benefit when Bevacizumab was added to first line chemotherapy for patients with metastatic disease, a trial addressing the benefit of both concurrent and maintenance bevacizumab for locoregionally advanced cervical cancer will likely need to be done," Schefter says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. ALS patients differ on treatment choices in later phases of disease
2. Reach2HD, a Phase II study in Huntingtons disease, launched
3. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
4. Phase III trial of dapivirine ring begins in Africa: New HIV prevention approach for women
5. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
6. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
7. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
8. Positive results from Phase 1/2 stem cell trial reported
9. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
10. Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
(Date:7/31/2015)... ... 2015 , ... Recently touted by Becker’s Healthcare as one ... , Jvion continues to disrupt the predictive analytic and big data market using ... population level illness to drive prevention and better health outcomes. Most recently, Jvion ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride ... in Downtown Memphis on October 3, 2015. The Ride to Fight On is a ... research between Methodist Healthcare, The West Clinic and The University of Tennessee Health Science ...
(Date:7/31/2015)... ... 2015 , ... There’s no better way to enjoy the summer weather than ... the next meal, making July the most appropriate to be National Hot Dog Month. ... , Make the next cookout different than the ones in the past. Celebrate National ...
(Date:7/31/2015)... ... 31, 2015 , ... Facebook, Twitter, Linkedin and blogs are ... media profiles to better connect with the public. The agency website at ... insights and opinions. The Rally Insurance Group, Inc.’s pledge to provide effortless ways ...
(Date:7/31/2015)... , ... July 31, 2015 , ... M3 USA MDLinx.com, ... to launch three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology ... Exam Prep from MDLinx makes preparing for the exam easy and painless. MDLinx ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... Oct. 29 The Ensign,Group, Inc. (Nasdaq: ... group of,skilled nursing, rehabilitative care services and assisted ... skilled nursing,facilities in Texas and California for an ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ), Previously leased facilities now owned, ...
... Respectively, MEXICO CITY, Oct. 28 , Financial ... millions of Mexican pesos,as of December 31, 2007 while ... current Mexican pesos. Comparisons are made with the same,period ... to rounding,practices. "bp" stands for basis points), ...
... 28 Today the ... responded to a request ... to hold an unnecessary,debate., ... letters, please visit:, http://www.noonprop8.com/downloads/FSchubert102808.pdf ...
... Oct. 28 The Ensign,Group, Inc. (Nasdaq: ... group of,skilled nursing, rehabilitative care services and assisted ... its third quarter 2008,financial results following the market ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ), Conference Call, Ensign ...
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer and ... announced that it will release,financial results for the ... close on Monday, November 3, 2008. The Company ... November 3, 2008 at 5:00 p.m.,Eastern Time (2:00 ...
... Va., Oct. 28 Professional Healthcare,Resources, Inc., one ... based in the Washington, DC metropolitan area, is ... the 2008 Homecare Elite. The,selection was made by ... healthcare information agency and Decision Health(TM), a Rockville,MD ...
Cached Medicine News:Health News:The Ensign Group, Inc. Acquires Four Skilled Nursing Facilities 2Health News:Grupo Casa Saba Quarterly Earnings Report 3Q08 2Health News:Grupo Casa Saba Quarterly Earnings Report 3Q08 3Health News:Grupo Casa Saba Quarterly Earnings Report 3Q08 4Health News:The Ensign Group Schedules 2008 Third Quarter Earnings Call for Friday, October 31, 2008 2Health News:ATS Medical Announces Third Quarter 2008 Earnings Release Date and Conference Call 2Health News:Professional Healthcare Ranked Among the Top 25 Percent of Home Health Care Providers in the Country for 2008 2Health News:Professional Healthcare Ranked Among the Top 25 Percent of Home Health Care Providers in the Country for 2008 3
(Date:7/30/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today ... Agreements with Dexcom, Inc. to allow the integration ... Dexcom G5 and G6 continuous glucose monitoring ("CGM") ... platform with Dexcom,s future CGM systems is an ...
(Date:7/30/2015)... N.J. , July 30, 2015  Unichem Pharmaceuticals ... recalling one lot of Hydrochlorothiazide tablets 25 mg 1000-count ... initiated as a precautionary measure due to the identification ... the product. The risk associated with ... tablet is the increased probability of experiencing Clopidogrel,s side ...
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the second quarter ending June 30, 2015. ... the organization.  We are excited to be near the ... ever conducted with topline results expected in the fourth ... PTC Therapeutics, Inc. "Translarna is now commercially available in ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... MYL ) today announced that its subsidiary Matrix Laboratories ... Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) ... mg, the generic version of Pfizer,s Neurontin ® Capsules ... Gabapentin Capsules had U.S. sales of approximately $300 million ...
... 2011 PAREXEL International Corporation (Nasdaq: ... the Raymond James Investors Conference in Orlando, FL.  James Winschel, ... a presentation on PAREXEL at 2:50 p.m.  ET on Monday, ... presentation will be available through the "Investors" section ...
Cached Medicine Technology:PAREXEL International to Present at Raymond James Investors Conference 2
The Vision Premier software features advanced,capabilities, including automatic categorization,of beats, tachogram review and full-disclosure,viewing, providing the tools needed for even,the ...
The Deltec Cozmo® insulin pump is small, about the size of a cell phone, and only weighs 3.3 ounces (w/ battery and full cartridge). Its ergonomic design fits comfortably in the palm of your han...
The IR 1000 Insulin Infusion Pump from Animas offers unprecedented safety features, performance, and convenience....
... was designed specifically to meet the varying needs ... a simple to use, compact, dual application system ... field of light based hair removal. SpaTouch works ... safe for use on nearly all face and ...
Medicine Products: